Skip to main contentAll experts

David Iglesias

CHIEF & CLIN ASO PROF

MD-OBSTETRICS - GYNECOLOGY

Orcid identifier0000-0002-8506-3451 (opens in a new tab)⁠
  • CHIEF & CLIN ASO PROF
    MD-OBSTETRICS - GYNECOLOGY

GRANTS

  • GRANT
    A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
    Merck Sharp & Dohme10 Nov 2025 - 9 Nov 2030
    Active
  • GRANT
    Complementary Utility of Two HPV Biomarkers to Optimize Response and Personalize Cervical Cancer Treatment
    Florida Department of Health24 Sep 2025 - 31 Mar 2027
    Active
  • GRANT
    A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
    National Institute of Health Nci16 Oct 2023 - 28 Feb 2029
    Active
  • GRANT
    A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum#
    Novartis Pharmaceuticals Corporation1 Apr 2019 - 8 Feb 2027
    Active
  • GRANT
    A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
    National Institute of Health Nci4 Sep 2018 - 28 Feb 2026
    Expired